The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.
BACKGROUND Recently, several combined therapeutic strategies and targeted agents have been under investigation for their potential role in lung cancer. The combined administration of dendritic cells (DCs) and immune-adjuvant cytidyl guanosyl oligodeoxynucleotide (CpG-ODN) after cryosurgery has proven to be an effective strategy for treating lung cancer. However, whether the application of CpG-ODN could affect the therapeutic results remained to be further explored. MATERIAL AND METHODS The Lewis lung cancer (LLC)-bearing mice received cryoablation and injection of ex vivo-cultured DCs into the peritumoral zone. Subsequently, CpG-ODN was administered to experimental animals 6 hours, 12 hours, and 24 hours after DC injection. The mice in the control group received coadministration of DCs and CpG-ODN simultaneously. Therapeutic effects were evaluated by survival rates. The resistance to rechallenge of LLC cell was assessed by lung metastasis and in vitro cytotoxicity of splenocytes. Furthermore, T-cell subsets and multiple cytokines (interleukin [IL]-4, -10, and-12; interferon [IFN]-γ; tumor necrosis factor [TNF]-α) in the blood were assessed to elucidate the underlying mechanisms. RESULTS Higher ratios of CD4+ and CD8+ T cells and higher levels of IL-12, IFN-γ, and TNF-α were found in the blood of the mice that received CpG-ODN therapy 12 h after DC injection. The cytotoxicity potency of the splenocytes of these mice was significantly higher compared with the mice in other groups. Moreover, the mice receiving CpG-ODN therapy 12 h after DC injection showed significantly better resistance to rechallenge. Compared with the mice in other groups, the mice receiving CpG-ODN therapy 12 h after DC injection were superior in survival rates and antimetastatic effects. CONCLUSIONS Our study suggested that the therapeutic efficacy was closely associated with CpG-ODN administration in the combined therapeutic protocol of cryoablation, DCs, and immune adjuvant. In situ administration of CpG-ODN 12 h after DC injection might be considered the optimum application.
Department of Respiration, General Hospital of Chinese PLA, Beijing, China (mainland).
Mi
M
Zhang
Department of Emergency, Beijing Chaoyang Hospital Afﬁliated to Capital Medical University, Beijing, China (mainland).
Tianquan
T
Yin
Department of Respiration, General Hospital of Chinese PLA, Beijing, China (mainland).
Yuan
Y
Lu
Department of Respiration, General Hospital of Chinese PLA, Beijing, China (mainland).
Huasong
H
Feng
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D018899:CpG Islands; D003452:Cryosurgery / Q000379:methods*; D016207:Cytokines / Q000097:blood; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D005260:Female; D016219:Immunotherapy, Adoptive / Q000379:methods*; D018664:Interleukin-12 / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D011897:Random Allocation; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D009838:Oligodeoxyribonucleotides; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12